Third time’s the charm: Fangzhou finally finds winning tonic for Hong Kong IPO
The company has become the latest internet healthcare stock to list, but continues to lose money and remains heavily reliant on drug sales Key Takeaways: Fangzhou has been approved to…
Recent Articles
RELATED ARTICLES
-
BRIEF: Fangzhou adjusted profit jumps 139% on improving technology, efficiency
6086.HK -
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
